Yuhan Corporation Tops Pharmaceuticals Category of "Korea's Most Admired Companies" for 23 Consecutive Years

Organized by KMAC... Never Missed the Top Spot

Yuhan Corporation announced on the 11th that it has been ranked No. 1 in the pharmaceuticals category of the "2026 Korea's Most Admired Companies" organized by Korea Management Association Consulting (KMAC).

Yuhan Corporation was selected as the No.1 company in the pharmaceutical sector of the "2026 Most Respected Companies in Korea" survey organized by Korea Management Association Consulting (KMAC). Han Soohee, CEO of Korea Management Association Consulting (left), and Lee Byungman, Head of Management Division (Executive Vice President) at Yuhan Corporation, pose for a commemorative photo. Photo by Yuhan Corporation

The "Korea's Most Admired Companies" survey was established in 2004 with the aim of presenting a desirable model for corporate management and enhancing the competitiveness of Korean industries. Yuhan Corporation has not missed the top spot in the pharmaceuticals category even once during the 23 years the Korea's Most Admired Companies awards have been held.

Celebrating its 100th anniversary, Yuhan Corporation has long been loved under the corporate image of "Willow Mark Yuhan, a Symbol of Trust," as it has carried on the founding spirit of the late founder, Dr. Ilhan New. Going beyond the pursuit of profit to focus on creating social value, the founder's aspiration for a healthy population and a happy society is being realized through Yuhan Corporation, the Yuhan Foundation, and Yuhan School.

Alongside practicing ESG (environmental, social, and governance) management, the company is also focusing on securing future growth engines through the development of innovative new drugs. Lazertinib, marketed as "Leclaza," the 31st domestically developed new drug in Korea and a treatment for non-small cell lung cancer, was granted U.S. FDA approval in August 2024 as the first Korean anticancer drug to be authorized in combination therapy with Johnson & Johnson's "Rybrevant," thereby gaining recognition for its global innovativeness. Subsequently, as indication expansion and approval processes in major markets such as Europe, China, and Japan have begun in earnest, the drug is achieving results in the global anticancer market.

This content was produced with the assistance of AI translation services.